focus new market/margin opportun initi
outperform
initi coverag outperform pt manufactur
medic devic use sever type procedur intervent diagnost
therapeut across numer market cardiolog endoscopi oncolog
radiolog among other recent share pressur due sales/gross margin miss
guide-down sale mix impact gm challeng need
address see avenu improv higher margin drainag
cathet embotherapi clarivein busi plant consolid reduc
one-tim cost mdr-relat also help gm new fluid manag
opportun gm-accret posit ebitda given point
believ valuat attract discount peer
diversifi busi one posit stori diversifi revenu base
almost sale outsid us china revenu driver well
sale note sell sever major market
one product drive sale top sell product repres
new improv opportun number revenu opportun open
near term includ market-shar gain potenti embol bead
follow recent divestitur busi varian build oncolog
franchis follow cianna acquisit late share captur
opportun fluid manag follow new gpo agreement premier
margin thought gross margin light sale mix primari
driver potenti increment driver look forward includ clarivein
impact distributor inventori workdown embotherapi share gain highest
margin product portfolio aspira drainag cathet becton
dickinson put focus sale forc place start late address
lower expect sale
risk near-term invest opex remain steadi improv
gm ahead key overal ebitda leverag activ
lead integr trip-up higher expect clarivein distributor
inventori level exampl face formid competitor
estim forecast sale y/i ex-
acquisit fx ep forecast oper incom
growth higher tax rate lead slower ep
look sale growth cc ep
includ gm expans
year price histori
dispos medic devic use
manufactur broad array product
span sever cardiovascular
analyst certif import disclosur see disclosur
rate outperform price target recent share
pressur due sales/gross margin miss guid
sale mix impact gm challeng need
address see avenu improv
compani higher margin drainag cathet embotherapi
clarivein busi plant consolid reduc one-tim
cost also help gm new fluid manag
opportun gm accret posit ebitda
given point believ valuat attract
discount
increment contribut new opportun includ cianna
gross margin expans mid- low end manag
guidanc rang
opex remain larg steadi percentag sale
improv perform clarivein drainag becton
gross margin expans plant consolid roll-off mdr
share gain fluid manag embol
stronger gross margin expans led mix forecast
expans versu management goal
greater expect share captur fluid manag
higher margin product fail stabil clarivein drainag
failur captur increment share fluid manag embol
target price driven blend dcf compar price-to-earnings multipl dcf assum ebit growth rate
wacc ebitda termin growth rate price target impli price-to-earnings multipl
ep estim still discount peer current trade reach price target could make target
multipl conserv increas visibl gross margin expans led higher-margin new product flow
risk includ failur achiev gross margin leverag competit end-market macro pressur tariff brexit
medic devic manufactur dispos medic
devic use intervent diagnost therapeut procedur compani
manufactur broad array product span six major product categori
peripher intervent cardiac intervent cardiovascular critic
intervent oncolog spine cianna medic breast cancer local
guidanc endoscopi found compani base south jordan ut
gener sale year/year pro forma
shift radial access increasingli intervent cardiolog procedur
perform radial arteri access tradit femor access radial access
also known transradi approach cathet access arteri
patient wrist perform endovascular procedur transradi access
potenti decreas vascular complic reduc access site bleed complic
allow earlier patient ambul potenti lower hospit cost
shorter hospit stay manag highlight signific increas penetr
radial procedur us level still trail europ asia suggest
full complement access product cover spectrum approach
cardiac peripher intervent includ set-up board ial arm board
board use provid support radial access procedur access famili
prelud introduc sheath femor radial access angiographi inqwir
guid wire performa diagnost cathet featur consist superior torqu
larg inner diamet improv flow rate high shaft strength pushabl
intervent asap aspir cathet cathet use remov fresh soft emboli
thrombi vessel quadraspher microspher design precis
calibr embol control target embol hemostasi safeguard radial
compress devic hemostasi devic deliv modifi activ compress
enabl immedi pressur adjust kit custom radial kit cardiolog
procedur tray pack kit peripher
build portfolio oncolog mmsi acquisit cianna medic complet
novemb bolster compani focu intervent oncolog
scout fda clear ce mark pend wire-fre breast tumor local
system design produc audibl visual indic assist surgeon
mark cancer tissu biopsi lumpectomi procedur
savi brachi fda ce mark clear brachytherapi cathet use
thin tube deliv radiat directli lumpectomi site
time acquisit indic scout track gener
us sale estim share us market addit
use breast cancer scout technolog potenti indic accord
manag includ lung liver
cianna acquisit ad mmsi oncolog portfolio alreadi includ
embolotherapi product design treat diseas slow block flow
blood arteri deliv chemotherapi drug treatment metastat
primari liver cancer microcathet merit pursu microcathet small
microcathet design pushabl trackabl tortuou small vessel
biopsi product includ corvocet biopsi system util cut
full-cor tissu provid larg specimen patholog examin
increment embol opportun august final
purchas boston scientif drug-load microspher bland embol bead
product treat arterioven malform hypervascular tumor
divestitur follow complet acquisit btg plc
requir secur anti-trust clearanc includ clearanc us feder trade
commiss drug-load microspher bland embol bead
product sale origin acquir
embol portfolio celonova bioscienc product includ spheric embol
product use treat uterin fibroid condit drug-elut microspher
design load chemotherapi drug deliveri cancer tumor
lost meaning market share manag recent estim lost upward
account us howev divestitur shift portfolio
varian potenti upsid captur market share grow embol
busi assum slight pickup growth low teen low singl digit
overal sale level among mmsi smallest annual
mmsi embolotherapi portfolio includ quadraspher microspher design
precis calibr embol control target embol hepaspher
microspher use treatment primari metastat liver cancer offer
outsid us embol product highest margin product overal
embol busi gross margin rang
one mmsi latest embol product embocub pre-load syring fill
gelatin foam specif design address prepar concern inconsist
particl size associ use tradit gelatin foam sheet embol
product launch indic use embol hypervascular
tumor prior embocub physician prepar gelatin foam embol agent
endovascular procedur requir manual prepar gelatin foam use
time-consum result inconsist size particl may
potenti clog deliveri cathet lead nontarget embol
product design manag patient fluid level imag media wast diagnost
intervent procedur product rang tube transduc fluid spike
drainag bag june award group purchas agreement
intervent fluid manag product premier inc network
us hospit provid agreement effect juli
allow premier member leverag negoti term mmsi intervent
fluid manag product believ exclus contract increas visibl
rang portfolio product enabl potenti cross-sel opportun
april announc agreement sell namic fluid
manag busi medlin industri inc divestitur creat
potenti us opportun captur market share fluid
manag space given mani custom also medlin
competitor thu potenti reserv purchas medlin see
increment tailwind opportun leverag fluid manag
activ past sever year ad complementari
product sale rep bag importantli mani transact includ
product gross margin profil accret compani three recent
acquisit deal includ brightwat medic vascular insight cianna
medic
brightwat medic primari product convertxa singl devic use
replac seri devic procedur treatment sever obstruct
ureteri complementari mmsi resolv drainag cathet portfolio convertx also
synergist mmsi inqwir guid wire advoc pta balloon vascular
product convertx design reduc hospit visit well prevent risk
discomfort second intervent procedur product well posit within
rang convertx manufactur oper transfer mmsi
pearland tx facil highli accret core gross margin
vascular insight primari asset consist clarivein ic fda clear
clarivein oc ce-mark specialti infus occlus cathet system
clarivein system address global market util
treatment superfici venou diseas mainli knee btk venou leg
ulcer vlu case vascular insight acquisit complement
mmsi exist peripher intervent platform increas abil custom
entir procedur custom allow cross-sel exist product
micropunctur vascular access product gross margin non-gaap
basi expect accret clarivein system non-gaap
gm time acquisit
last cianna medic acquisit acceler mmsi women health oncolog
portfolio complementari compani biopsi busi gross margin
non-gaap basi expect accret cianna product
mmsi intern revenu total revenu reach
small-cap compani mmsi alreadi establish larg intern
presenc differenti help mitig geograph risk provid base new
growth opportun china repres signific amount intern sale
sale total total revenu despit on-going tariff situat
us china impact margin compani continu
see solid top-lin growth china
respect product diversif note offer wide spectrum
product span numer market help mitig signific competitor market
deceler risk one market top ten product account
approxim total sale
long term highlight wrapsodi new endovascular stent graft use
upper extrem signific pipelin opportun wrapsodi place
target lesion damag follow use picc line central line
dialysi cathet compani note current product market
approv type procedur current conduct two separ
clinic trial phase studi use wrapsodi treatment venou outflow
circuit obstruct hemodialysi patient phase studi use wrapsodi
treatment iliac arteri occlus diseas estim wrapsodi project
potenti gener annual revenu earli believ futur
pipelin product differenti play market growth catalyst
announc dateclos datetargettransact valueev/sal product jun jun medic inc intervent dec may insight llc oct medic inc medic inc feb dickinson co product lines/ becton dickinson oct oct healthcar pti ltd itl procedur jul jul llc oncolog feb feb connect inc critic jan jan medic devic inc /critic business/ argon medic devic critic jul jul inc oncolog feb feb inc /hero graft brand/ outperform
gross margin lighter expect manag reduc full-year
gross margin guidanc manag focus near-term opex invest
drive sale growth leverag gross margin key margin expans near-term
failur improv growth clarivein aspira higher gross margin
product slower expect growth could lead gross margin thu
ebit margin under-perform believ expect cost save
malvern pa manufactur consolid reduc mdr cost offset
potenti upsid even sale mix doesnt improv expect
success integr acquisit risk
uncertainti associ shouldnt dismiss particularli given pace
activ engag acquir clarivein product
unexpect sale shortfal fall behind owe unexpect excess distribut
inventori distributor channel call manag indic believ
destock behind compani
manag also indic acquir aspira drainag busi product
becton acquisit fell slightli behind forecast achiev biopsi product
becton perform well near term focus improv drainag
busi sale recent move peripher intervent sale rep
began june focu target biopsi drainag product bag medium
term focus drive product enhanc extens aspira
portfolio manufactur move in-hous becton mmsi facil mexico
target
face formid competit across portfolio compet larg global
includ oper previous conduct btg plc abbott
other intervent cardiolog intervent radiolog gastroenterolog
endoscopi gener surgeri thorac surgeri pulmonolog space mmsi product
divers off-set tough competit need monitor
peripher intervent product use support minim invas diagnosi
treatment diseas within peripher vessel organ throughout bodi
exclud heart mmsi peripher intervent product line categor
access dialysi graft offer includ subcutan vascular access system
use maintain long-term vascular access patient chronic hemodialysi
hemodialysi cathet mmsi surfac inside-out access cathet
method restor access give hemodialysi patient occlud vein
option preserv treatment option
angiographi angiographi product util identifi blockag
diseas state blood vessel product includ hydrophil guid wire
smooth-surfac guid wire diagnost cathet
intervent intervent product princip use place balloon stent
treat arteri diseas remov blood clot retriev foreign bodi blood vessel
includ percutan translumin angioplasti pta cathet correct fail
thrombos dialysi fistula infus system treatment arteri
hemodialysi graft occlus deep vein thrombosi aspir cathet use
remov soft emboli thrombi vessel mmsi stent graft balloon
cathet use repair abdomin aortic aneurysm thorac aortic aneurysm within
abdomin thorac endovascular aneurysm repair procedur
decemb acquir asset vascular insight llc
product includ clarivein ic fda clear clarivein oc ce-mark
specialti infus occlus cathet system system use
treatment superfici venou diseas particularli btk vlu address
platform synergist micropunctur vascular access product
clarivein system util case
drainag key/standout drainag product includ one-step valv one-step
drainag cathet use emerg drainag procedur quickli remov
unwant fluid accumul sold individu kit biliari cathet
drainag bag tube set
februari expand drainag busi acquir aspira pleural
effus drainag aspira periton drainag system acquisit
divest asset becton acquisit bard aspira
system tunnel long-term cathet drain accumul fluid patient
malign pleural effus build-up fluid chest wall lung
malign ascit irregular accumul fluid within periton caviti caus
chest discomfort short breath common complic number
cancer addit aspira use home
needl biopsi product includ achiev programm automat biopsi system
becton product complementari mmsi princip soft tissu core needl
biopsi product includ corvocet biopsi system util cut full-cor tissu
provid larg specimen patholog examin suit bone spine
exhibit peripher intervent product clarivein achiev aspira
cardiac intervent access product use gain access heart includ
prelud introduc sheath femor radial access
angiographi product design identifi block narrow coronari arteri
includ guid wire diagnost cathet cathet design radial access
hemostasi product help maintain hemostasi stop flow blood follow
cardiac intervent product use coronari catheter procedur
includ stent align tool design precis stent implant aorto-osti
lesion guid cathet support cathet intend grasp cross tight difficult
cardiac rhythm manag offer solut
electrophysiolog product includ deliveri system insert
implant left ventricular pace lead trans-sept needl use left-heart access
procedur steerabl sheath introduc
cardiovascular critic
cardiovascular product includ dualcap disinfect protect system use
protect disinfect needleless valv isopropyl alcohol design reduc
healthcare-rel infect hospit shortstop temporari sharp holder use
hold needl prevent unintend needlestick injuri hospit employe backstop
dispos basin design hold contamin fluid wast safe effici wast
elimin addit blood pressur monitor product consist monitor devic
fluid manag devic provid valuabl inform physician help
expedit patient recoveri process
intervent oncolog spine
intervent oncolog spine product use treatment metastat
compress fractur arterioven malform hemostat embol
certain market outsid us intervent oncolog spine product
categor follow product portfolio
deliveri system includ guid wire microcathet design target
access control infus therapeut agent embol vessel product
includ microcathet design pushabl trackabl tortuou small
vessel guid wire design facilit navig complex anatomi
embolotherapi product use treat diseas slow block flow
blood arteri deliv chemotherapi drug treatment metastat
primari liver cancer receiv fda approv prostat arteri
embol pae provid non-surg treatment option men suffer
product includ microspher small spheric particl diamet rang
produc sever natur synthet polymer materi
even inorgan materi ceram polym microspher controlled-
releas drug-deliveri system use improv bioavail stabil target
drug specif site predetermin rate abil allow higher
concentr drug deliveri lower system concentr compar
tradit chemotherapi deliveri given rang method product
microspher offer numer opportun control characterist drug administr
aspect enhanc therapeut efficaci drug
spine system treat vertebr compress fractur caus cancer osteoporosi
inject bone cement small hole skin fractur vertebra
product includ stabilit vertebr augment design treat
patholog fractur deliv bone cement steadi viscos use
radio-frequ energi stabilit mx vertebr augment inflat devic
deliv bone cement stabilit vice-president vertebroplasti combin control deliveri
high-viscos cement simpl cement prepar osseoflex product
direct devic enabl user navig target specif anatomi within
tumor ablat portfolio brand tumor ablat system mmsi
system design provid palli treatment pain metastat spinal
tumor cancer patient use target radiofrequ ablat
accur posit ablat electrod extend deliveri radiofrequ
energi begin radiofrequ energi deliv site tumor
destroy reposit instrument perform addit target ablat
allow clinician treat larger area tumor reduc risk damag
exhibit intervent oncolog spine product embospher microspher
tumor ablat stabilit vertebr augment
cianna medicalbreast cancer local guidanc
complet acquisit cianna medic inc privat held compani
dedic treatment early-stag breast cancer novemb
cianna acquisit began sell savi brachytherapi breast radiat
design produc audibl visual indic assist surgeon mark
cancer tissu biopsi lumpectomi procedur cianna particularli
differenti leader breast tumor local technolog scout system
world non-radioact wire-fre radar breast local system scout
system use radiat wire instead use small staple-s reflector
target tissu procedur done day prior surgeri versu
day surgeri requir tradit wire local sophist
level local precis enabl better surgic plan surgeon potenti
improv cosmet result patient less good tissu may need remov
endoscopi segment consist gastroenterolog pulmonolog medic devic
help treatment expand esophag tracheobronchi biliari
strictur caus malign tumor endoscopi divis market product
gastrointestin pulmonari condit merit endotek brand merit endotek
product offer expand april includ nvisionvl imag
via world-wide distribut agreement ninepoint medic inc
nvisionvl imag design allow target biopsi esophagu
use optic signal acquisit process method creat high-resolut
cross-sect imag mark tissu visibl white light endoscopi mmsi
endoscopi segment also consist kit accessori product offer
endoscopi bronchoscopi procedur
non-vascular stent use treat pulmonari gastrointestin diseas
product includ aero aeromini aero dv fulli cover tracheobronchi
stent use treatment tracheobronchi strictur form malign
neoplasm abnorm mass tissu alimaxx- endomaxx fulli cover
esophag stent design maintain esophag lumin patenc esophag
strictur produc intrins and/or extrins malign tumor well occlus
esophag fistula alimaxx-b biliari stent system use palliat
malign strictur biliari tree
dilat balloon use endoscop dilat strictur product includ
balloon dilat design use digest tract well dilat strictur
trachea bronchi inflat devic syring gaug use
inflat deflat non-vascular balloon dilat monitor display inflat
pressur atmospher
specialti procedur product clinician custom often requir custom
need perform procedur work close end user creat
custom tray pack kit enabl clinician perform procedur
effect addit manufactur sell microelectromechan system sensor
compon compris pressur sensor numer form
esophag stent elat pulmonari balloon dilat
second-quart miss guidanc reduct sale y/i
miss analyst estim ep miss analyst
forecast due gross margin pressur product sale mix fx headwind
sale miss came higher fx headwind well unexpect sale
under-perform clarivein higher expect inventori distributor
channel aspira fall behind forecast lower
guidanc adjust fx headwind chang product mix previous announc
dilut brightwat acquisit revis full-year sale guidanc
previou guidanc includ estim
increment fx headwind year versu prior think
non-gaap gross margin guidanc lower previou guidanc
fx headwind unfavor sale mix associ intervent
oncolog spine portfolio aspira sale cite ep guidanc rang
previou due fx headwind approxim
charg relat brightwat acquisit
opco forecast forecast sale includ acquisit
exclud acquisit fx led cathet product segment
assum increment conserv contribut market share gain embol
bead follow recent divestitur busi varian share
captur opportun fluid manag follow sale fluid
manag medlin recent secur premier purchas agreement
look gross margin look improv
sequenti assum pickup clarivein sale manag
indic call believ distributor inventori workdown behind
compani increment contribut embotherapi share gain highest margin
product portfolio lower fx headwind versu sg
percentag sale increas invest
includ clinic support train program manag note expect
increas focu tighten expens howev follow gross margin shortfal
look oper incom growth full year compar higher tax
rate versu versu lead slower ep growth versu
oper incom growth estim
opco forecast look sale growth constant
currenc led cianna medic cathet follow
expect contribut brightwat medic acquisit manag
also target acceler brightwat convertx product sale
forc bag guid potenti fifth full year sale forecast
earn call manag provid guidanc sale growth
gross margin expans ep growth rang follow
miss manag re-affirmed goal though lower base
forecast gross margin expans though lower end manag
guidanc point contributor includ malvern
manufactur facil shutdown lower one-tim european mdr cost assum
oper expens remain larg percentag sale though
manag note potenti increas focu leverag
model assum signific impact stock option expens benefit
tax rate thu forecast slightli slower growth ep versu oper
incom
focu gross margin leverag gross margin contract bp y/i
partial due neg product sale mix io divis lower expect
aspira sale aim make structur chang order drive gross margin higher
time includ plant consolid meantim process shift
manufactur product malvern manufactur facil mexico on-going
facil shift expect complet expect increment
posit cost save cost save translat bp gross
margin accret
cash june conjunct announc
acquir dfine inc total transact valu juli
enter second amend credit agreement lender second amend
credit agreement consist term loan facil revolv credit facil
total princip amount matur date juli
june fix rate debt result
interest rate swap variabl float rate current borrow
capac credit facil
follow miss guidanc reduct share trade discount
forward price-to-earnings multipl versu four-year averag premium target
price driven blend dcf compar price-to-earnings multipl dcf assum
year ebit growth rate wacc ebitda termin
growth rate price target impli price-to-earnings multipl ep
estim still slight discount peer current trade
reach price target could make target multipl conserv
increas visbl gross margin expans led higher-margin new product flow
epsep growthnon-gaap p/ecompanytickerr medic inc class lifesci hold hold comp estim factset compani report oppenheim co estim result present view indic futur perform nc cover outperform perform under-perform inc
fred lampropoulo found serv chief
execut offic sinc prior mr lampropoulo serv chairman
ceo utah medic mr lampropoulo former special forc
offic honorari colonel utah nation guard hold number
honorari doctor includ doctor busi administr westminst
colleg lake citi
raul parra jr serv chief financi offic
sinc juli previous mr parra serv variou account role sinc
merit prior merit account role deloitt touch llp
mr parra hold bachelor scienc degre busi administr
sonoma state univers certifi public account
ronald frost chief oper offic serv
multipl role merit year span engin relat role
vice presid materi oper mr frost receiv undergradu degre
weber state univers
stock price compani mention report
equival
prepaid expens
liabil relat unrecogn tax benefit
oper activ
sale pp
write-off patent intang asset
amort defer credit
amort long-term debt issuanc cost
chang current asset liabil
liabil relat unrecogn tax benefit
net oper
invest
proce sale pp
net invest
financ
proce long-term debt
payment long-term debt
conting payment relat acquisit
net financ
effect exchang rate
net increas decreas
